These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37561342)

  • 1. ASO Author Reflections: Clinical Outcome After Upfront Curative-Intent Local Treatment of Metastases in Patient with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer.
    Zwart K; Roodhart J
    Ann Surg Oncol; 2023 Oct; 30(11):6771-6772. PubMed ID: 37561342
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort.
    Zwart K; van der Baan FH; Punt CJA; Wensink GE; Bolhuis K; Laclé MM; van Grevenstein WMU; Hagendoorn J; de Hingh IH; Koopman M; Vink G; Roodhart J
    Ann Surg Oncol; 2023 Oct; 30(11):6762-6770. PubMed ID: 37528303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASO Author Reflections: Mismatch Repair and Survival in Metastatic Colorectal Cancer.
    Sherman SK; Chan CHF
    Ann Surg Oncol; 2020 Dec; 27(13):5084-5085. PubMed ID: 32627118
    [No Abstract]   [Full Text] [Related]  

  • 4. Characteristics of
    de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
    Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
    Overman MJ; Ernstoff MS; Morse MA
    Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial.
    Gögenur M; Balsevicius L; Bulut M; Colak N; Justesen TF; Fiehn AK; Jensen MB; Høst-Rasmussen K; Cappelen B; Gaggar S; Tajik A; Zahid JA; Bennedsen ALB; D'Ondes TDB; Raskov H; Sækmose SG; Hansen LB; Salanti A; Brix S; Gögenur I
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37172969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer.
    Huang Q; Yu T; Li L; Zhang Q; Zhang S; Li B; Li X; Xiao W; Liu G
    Appl Immunohistochem Mol Morphol; 2023 Feb; 31(2):84-93. PubMed ID: 36409630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What are the optimal first-line therapies for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer?
    Taira K; Kimura A; Nakata A; Tanaka F; Nagami Y; Fujiwara Y
    Ann Palliat Med; 2023 May; 12(3):607-610. PubMed ID: 37038074
    [No Abstract]   [Full Text] [Related]  

  • 9. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Grade Is Prognostically Relevant Among Mismatch Repair Deficient Colorectal Carcinomas.
    Johncilla M; Chen Z; Sweeney J; Yantiss RK
    Am J Surg Pathol; 2018 Dec; 42(12):1686-1692. PubMed ID: 30179899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].
    Chen K; Liang H; Peng J; Zheng Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Nov; 38(11):1300-1305. PubMed ID: 30514676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
    Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
    N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy with pembrolizumab in treatment-naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer.
    Eefsen RL; Larsen JS; Klarskov LL; Altaf R; Høgdall E; Ingeholm P; Lykke J; Nielsen DL; Pfeiffer P; Poulsen LØ; Qvortrup C; Schou JV; Mau-Sørensen M; Østerlind K; Jensen BV
    Int J Cancer; 2023 May; 152(10):2145-2152. PubMed ID: 36594580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of immunotherapy in a young patient with mismatch repair-deficient rectal cancer - a case report.
    Sokop T; Obermannová R
    Klin Onkol; 2023; 36(3):241-245. PubMed ID: 37353353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.
    van der Heide DM; Turaga KK; Chan CHF; Sherman SK
    J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.
    Lugli A; Tzankov A; Zlobec I; Terracciano LM
    Mod Pathol; 2008 Nov; 21(11):1403-12. PubMed ID: 18587323
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.